Skip to main content

Table 5 The sensitivity analysis at 25% sharing rate for marginal annual cost saving, cost - effectiveness and cost – benefit of SIF in Montreal

From: A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada

Variables Annual cost of operation Sharing rate # of HIV averted # of HCV averted HIV cost saved HCV cost saved Cost-effectiveness ratio HCV Cost-effectiveness ratio HIV Cost-benefit ratio HCV Cost-benefit ratio HIV
Post SIF $2,182,800 25% 10 64 -$77,250 $66,352 $34,106 $218,280 1.03 1
Two SIF $2,182,800 20% 9 55 -$287,805 -$249,935 $39,687 $242,533 0.89 0.87
Three SIF $2,182,800 15% 4 24 -$1,340,580 -$1,339,368 $90,950 $545,700 0.39 0.39
Four SIF $2,182,800 13% 4 24 -$1,340,580 -$1,339,368 $90,950 $545,700 0.39 0.39
Five SIF $2,182,800 11% 4 24 -$1,340,580 -$1,339,368 $90,950 $545,700 0.39 0.39
Six SIF $2,182,800 9.00% 4 24 -$1,340,580 -$1,339,368 $90,950 $545,700 0.39 0.39
Seven SIF $2,182,800 7% 4 24 -$1,340,580 -$1,339,368 $90,950 $545,700 0.39 0.39
Average $2,182,800 14% 6 34 -$919,470 -$987,938 $64,200 $363,800 0.55 0.58